Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Filings
28 filings of IPCALAB since November 2024.
board outcome 12, transcript 9, results 2, dividend 2, credit rating 2, scheme 1
| Filed | Type | Subject | |
|---|---|---|---|
| 06 Nov 2026 | transcript Guidance, Results | IPCA Laboratories Limited has informed the Exchange about TranscriptAI summaryIpca Laboratories filed the transcript of its Q2 FY27 earnings conference call held on 5 November 2026 (filed 6 November 2026 under Regulation 30). Management said consolidated revenue grew about 14% to around INR2,910 crores (vs INR2,557 crores), with consolidated EBITDA margin of 22.97% (vs 21.68%) and standalone EBITDA margin of 26.6% (vs 25.46%). Management said domestic formulations grew about 14% to INR1,157 crores and standalone export formulations grew 32% to INR653 crores. Management said it is not revising guidance: growth of 14% to 16% and consolidated EBITDA margin of 22% to 23% for FY27 stand, and it expects EBITDA margin to improve by about 1% to 1.25% a year. Management said the company is effectively debt-free apart from a small rupee term loan of about INR155 crores, with about INR700 crores of cash. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2026 | board outcome Results | IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryIpca Laboratories filed its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, approved at the Board meeting held on November 5, 2026, along with a limited review report and press release. Standalone revenue from operations for Q2 FY27 was Rs 2,255.61 crore, against Rs 2,119.24 crore in Q1 FY27 and Rs 1,930.32 crore in Q2 FY26 (as printed in the table). Standalone net profit for Q2 FY27 was Rs 387.29 crore, against Rs 304.74 crore in the corresponding quarter of the previous year; half-year net profit was Rs 760.58 crore. Basic/diluted EPS for Q2 FY27 was Rs 15.27 (not annualised), and half-year EPS was Rs 29.98 (before exceptional items). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Aug 2026 | transcript Guidance, Results | IPCA Laboratories Limited has informed the Exchange about TranscriptAI summaryIpca Laboratories filed the transcript of its Q1 FY27 earnings conference call held on August 14, 2026. Management said consolidated revenue grew about 21% to INR2,788 crores from INR2,309 crores, and consolidated EBITDA margin rose to 22.88% from 18.39%. Management said domestic formulation sales grew 13% to about INR1,082 crores, export business grew about 34% to about INR603 crores, and API business grew about 30% to about INR424 crores. Management said the 12% to 13% full-year growth guidance has been raised to about 14% to 16%, and the Unichem guidance of 10% portfolio growth and 13% EBITDA margin is not being revised for now. Management said institutional business is expected to stay in single-digit growth with annual sales of about INR260 crores to INR300 crores, and freight rates have risen sharply. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Aug 2026 | board outcome Acquisition, Results | IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryIpca Laboratories filed its unaudited standalone and consolidated Q1 FY27 results (quarter ended June 30, 2026) following the board meeting held on August 13, 2026, along with the auditors' limited review reports. Standalone revenue from operations for Q1 FY27 was ₹2,119.24 crores, against ₹1,746.90 crores in the year-ago quarter (June 30, 2025). Standalone profit for the period from continuing operations was ₹373.29 crores, against ₹262.04 crores a year earlier; total comprehensive income was ₹359.69 crores. Standalone basic EPS (not annualised) was ₹14.71 for the quarter, against ₹10.33 a year earlier. The quarter includes a ₹30.42 crore exceptional charge for the impact of the new Labour Codes on gratuity and leave liability. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Jul 2026 | credit rating Rating | IPCA Laboratories Limited has informed the Exchange about Credit RatingAI summaryIndia Ratings & Research (A Fitch Group Company) reviewed and affirmed Ipca Laboratories' credit ratings. Commercial paper of INR 500 million, maturity up to 365 days, affirmed at IND A1+. Bank loan facilities of INR 22,481.10 million (reduced from INR 25,937.30 million) affirmed at IND AA+/Stable/IND A1+. The CP is not carved out of the company's fund-based working capital limits. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Jun 2026 | scheme Acquisition, Legal | IPCA Laboratories Limited has informed the Exchange about Amalgamation/MergerAI summaryIpca Laboratories' board approved a Scheme of Amalgamation of its wholly owned subsidiary Krebs Biochemicals & Industries Ltd (Transferor) into Ipca Laboratories (Transferee), under Sections 230-232 of the Companies Act, 2013, with an appointed date of 1 April 2026. Ipca's standalone audited total income for FY ended 31 March 2026 was Rs. 7,431 crores; Krebs' audited total income for the same period was Rs. 26 crores, mostly conversion charges received from Ipca. The filing states the transaction is a related party transaction done at arm's length, and gives rationale including operational synergies, cost optimisation, and securing supply of fermentation-based APIs and drug intermediates. Under the scheme, Ipca will issue 7 equity shares of Re. 1 each for every 200 equity shares of Rs. 10 each held in Krebs, with no cash consideration; shares Ipca holds in Krebs will be cancelled without consideration. The scheme is subject to approvals under the Companies Act, 2013 and SEBI (LODR) Regulations, 2015. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Jun 2026 | board outcome Acquisition, Legal | IPCA Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 26, 2026.AI summaryIpca Laboratories' board approved a Scheme of Amalgamation of its subsidiary Krebs Biochemicals & Industries Ltd (transferor) into Ipca Laboratories (transferee), under Sections 230-232 of the Companies Act, 2013, with an appointed date of 1 April 2026. Ipca's standalone audited total income for FY ended 31 March 2026 was Rs. 7,431 crores; Krebs's audited total income for the same year was Rs. 26 crores, mostly conversion charges received from Ipca. The scheme is subject to necessary approvals under the Companies Act, 2013 and SEBI LODR Regulations, 2015, and is a related party transaction stated to be at arm's length. Rationale given includes operational synergies and cost optimisation, securing uninterrupted supply of fermentation-based APIs and drug intermediates to Ipca, and access to Krebs's fermentation API manufacturing capability, which Krebs's losses have limited. Consideration: no cash; Ipca will issue 7 equity shares of Re. 1 each for every 200 equity shares of Rs. 10 each held in Krebs (excluding Ipca's own holding, which will be cancelled), on a record date to be decided under the scheme. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Jun 2026 | transcript Guidance, Results | IPCA Laboratories Limited has informed the Exchange about TranscriptAI summaryIpca Laboratories filed the transcript of its Q4 FY26 earnings conference call held on 1 June 2026, with MD A.K. Jain and CS Harish Kamath. Management said consolidated FY26 revenue grew about 8% to INR9,646 crores and consolidated EBITDA margin was 20.72% (vs 19.94%); Q4 consolidated EBITDA margin was 20.52%. Management expects FY27 consolidated growth of about 12-13% and consolidated EBITDA margin of about 22-22.3%, and guided a 1-1.25 percentage point margin improvement for the year, mainly due to raw material cost pressure. Management said Unichem's EBITDA margin is expected to rise to about 12-13% in FY27 from about 8%, and that raw material costs could rise about 10-12% at current petroleum prices. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | dividend Dividend / buy-back, Management change, Results | IPCA Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 6 per equity share.AI summaryIpca Laboratories' board, at its meeting held on May 29, 2026, approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, along with a press release on the FY 2025-26 results. Standalone FY2026 revenue from operations was Rs 7,336.75 crore (FY2025: Rs 6,677.92 crore); standalone FY2026 profit for the period was Rs 1,132.52 crore... (FY2025: Rs 650.76 crore per the printed table, with figures partly garbled in OCR). The board recommended a dividend of Rs 6/- per share of Re 1/- each (600%) for FY ended March 31, 2026, subject to shareholder approval at the AGM, with Friday, August 7, 2026 fixed as the record date. The board approved re-appointment of Mr. Prashant Godha (DIN 00012759) as Executive Director for a further five years from August 16, 2026 to August 15, 2031, subject to shareholder approval at the AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | board outcome Dividend / buy-back, Management change, Results | IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryIpca Laboratories filed the outcome of its board meeting held on May 29, 2026, approving audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. Standalone FY2025-26 revenue from operations was Rs 7,336.75 crore (FY2024-25: Rs 6,677.92 crore); standalone FY2025-26 net profit was Rs 1,132.52 crore (FY2024-25: Rs 650.76 crore) per the statement shown. The board recommended a dividend of Rs 6 per share of Re 1 each (600%) for FY2025-26, subject to shareholder approval at the AGM, with August 7, 2026 fixed as the record date. The board approved the re-appointment of Mr. Prashant Godha (DIN 00012759) as Executive Director for 5 years from August 16, 2026 to August 15, 2031, subject to shareholder approval at the AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Feb 2026 | transcript Capex, Guidance, Results | IPCA Laboratories Limited has informed the Exchange about TranscriptAI summaryIpca Laboratories filed the transcript of its Q3 FY26 earnings conference call held on February 16, 2026, under Regulation 30 of the SEBI LODR Regulations. Management said domestic business grew about 12% in Q3 FY26, with IPM growth of about 8.9% in the quarter, and consolidated revenue rose about 6.5% to INR2,245 crores from INR2,393 crores (as printed); consolidated EBITDA margin was about 22.5% against 19.87% in Q3 FY25. Management said export formulations grew about 17% in Q3 and API was flat at about INR317 crores; standalone EBITDA margin improved to about 26.09% from about 24.25%. Management said Unichem's revenue declined about 2% in the quarter due to market share loss in key US products, which started from Q2 and may continue for one or two more quarters, with margins expected to be under pressure for one or two more quarters. Management said capex is limited to a solar project with an outlay of about INR50 crores, and the company had more than INR250 crores of cash in the bank. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | board outcome Acquisition, Capex, Results | IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryIpca Laboratories filed unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, approved by the Board on February 13, 2026, with a limited review report from statutory auditors. Standalone revenue from operations for Q3 FY26 was Rs 1,845.18 crores, against Rs 1,662.68 crores a year earlier; standalone net profit for the quarter was Rs 303.45 crores, against Rs 267.56 crores a year earlier. Nine-month standalone revenue from operations was Rs 5,522.40 crores and net profit was Rs 870.23 crores, against Rs 715.81 crores in the prior-year nine months. Q3 standalone results include an exceptional item of nil, while the prior-period exceptional items were impairments of Rs 173.00 crores on exposure in subsidiary Ipca Pharmaceuticals Inc. and Rs 108.54 crores on exposure in associate Krebs Biochemicals & Industries Ltd. The company acquired 100% equity interest in Unichem Laboratories Limited, Ireland, during the nine months and incorporated a wholly owned subsidiary in Germany during the quarter. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Jan 2026 | board outcome Acquisition, Legal | IPCA Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on January 13, 2026.AI summaryBoard outcome filing (Regulation 30) on 13 January 2026; board meeting ran from 10:15 am to 10:35 am. Ipca Pharmaceuticals Inc, USA (wholly owned subsidiary of the company) proposes to sell its entire shareholding in Bayshore Pharmaceuticals LLC, USA, a dormant step-down subsidiary, to Centaur Pharmaceuticals USA Inc for USD 400,000, subject to due diligence and approvals. The agreement is expected to be signed around 20 January 2026 and completed within 30 days of signing; the buyer is an unrelated party and the deal is not a related party transaction. Bayshore has no business, assets or liabilities other than share capital and a bank balance of about USD 5,200, though it holds state licences to distribute pharmaceuticals in the USA. The company also proposes to update its registered office address in MCA records to include the district (Mumbai), so it can file IEM applications; the physical address is unchanged. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Nov 2025 | transcript Guidance, Results | IPCA Laboratories Limited has informed the Exchange about TranscriptAI summaryIpca Laboratories filed the transcript of its Q2 FY26 earnings conference call held on 13 November 2025, with Managing Director A.K. Jain and Company Secretary Harish Kamath representing management. Management said domestic formulations grew about 8% in Q2 FY26, with Ipca's market growth outpacing the IPM (Ipca grew about 11.6% against market growth of 7.8%, per IQVIA), and expects 8% to 9% generic formulations growth in H2 FY26. Export formulations were about INR 493 crores in Q2 FY26 against INR 541 crores a year earlier, down about 9%; H1 FY26 was INR 941 crores against INR 937 crores in H1 FY25. API business grew about 28% in Q2 FY26 to about INR 408 crores from INR 319 crores; full-year API growth is expected at about 14% to 15%. Standalone EBITDA margin was 25.46% in Q2 FY26 against 22.89% in Q2 FY25; consolidated EBITDA margin was 21.68% against 19.1%, and management expects H2 margins about 1% better than the roughly 20% guidance. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Nov 2025 | board outcome Results | IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryIpca Laboratories filed unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, taken on record at the Board meeting held November 13, 2025 (meeting ran 11.30 a.m. to 1.35 p.m.). Standalone revenue from operations for Q2 FY26 was ₹1,930.32 crores, against ₹1,810.94 crores in Q2 FY25 (Sept 30, 2024 quarter). Standalone net profit for Q2 FY26 was ₹304.74 crores, against ₹244.12 crores in the corresponding quarter last year. Standalone revenue from operations for H1 FY26 was ₹3,677.22 crores and net profit was ₹566.78 crores, against ₹3,376.80 crores and ₹448.25 crores in H1 FY25. Basic/diluted EPS for Q2 FY26 (after exceptional items) was ₹12.01 per share of face value ₹1 (not annualised). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Oct 2025 | board outcome Acquisition, Capex | IPCA Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on October 17, 2025.AI summaryIpca Laboratories' board, at its meeting on 17 October 2025, approved the sale of its drug intermediates and APIs manufacturing unit at GIDC Industrial Estate, Ankleshwar, to M/s. Suleshvari Pharma Pvt. Ltd. on a slump sale basis. Consideration is Rs. 22.15 crores in cash, with completion expected on or before 31 December 2025, subject to GIDC consent for transfer of the leasehold rights. The unit generated revenue of Rs. 50.24 crores in FY ended 31 March 2025 (0.74% of the Company's total income), and its written down value is Rs. 15.80 crores. The company states the sale will not have a material impact on its business and financials; the buyer is not a promoter group or related party. The agreement is to be entered into in due course, subject to necessary consents. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2025 | transcript Guidance, Results | IPCA Laboratories Limited has informed the Exchange about Transcript of Conference Call held on 12th August, 2025AI summaryIpca Laboratories filed a transcript of its Q1 FY26 earnings conference call held on 12 August 2025, hosted by DAM Capital. Management said standalone EBITDA margin improved to 23.82% in Q1 FY26 from 22.22% in Q1 FY25, while consolidated EBITDA margin was 18.39% versus 18.52%; standalone net profit rose about 26% to around Rs. 262 crores and consolidated net profit rose 18% to around Rs. 234 crores. Management said domestic business grew about 10% in Q1 and that IQVIA-tracked growth was 11.6% against IPM growth of about 8%. Management said full-year topline growth guidance of 9%-10% is unchanged, but consolidated EBITDA margin expansion guidance is lowered from about 100 bps to about 75 bps, mainly due to lower Unichem margins. Management said Unichem's Q1 included an additional provision of about Rs. 12 crores from currency movement on a EUR 14 million European Competition Commission penalty provision, and about Rs. 8-10 crores of redundancy cost for closing its Ireland facility. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Aug 2025 | board outcome Results | IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryBoard of Ipca Laboratories approved and took on record the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025) on August 11, 2025; the meeting ran from 12.00 noon to 1.30 p.m. Standalone revenue from operations for the quarter ended June 30, 2025 was Rs 1,746.90 crores, against Rs 1,565.86 crores a year earlier. Standalone profit for the period from continuing operations was Rs 262.04 crores, against Rs 204.13 crores in the quarter ended June 30, 2024. Standalone basic EPS for the quarter was Rs 10.33 (not annualised), against Rs 8.05 a year earlier. The statutory auditors, NVC & Associates LLP, issued an unmodified limited review report on the standalone results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Jul 2025 | credit rating Rating | IPCA Laboratories Limited has informed the Exchange about Credit RatingAI summaryIndia Ratings & Research (A Fitch Group Company) reviewed and affirmed Ipca Laboratories' ratings on its bank facilities and commercial paper. Commercial paper of INR 500 million rated IND A1+ (affirmed); the CP is not carved out of fund-based working capital limits. Fund/non-fund based working capital limit of INR 20,150 million rated IND AA+/Stable / IND A1+ (affirmed). Long-term loan maturing 27.03.2028 of INR 3,787.3 million (reduced from INR 5,185.6 million) rated IND AA+/Stable (affirmed); proposed long-term loan of INR 2,000 million rated IND AA+/Stable (affirmed). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Jun 2025 | transcript Guidance, Results | IPCA Laboratories Limited has informed the Exchange about Transcript of Conference Call held on 30th May, 2025AI summaryIpca Laboratories filed the transcript of its Q4 FY25 earnings conference call held on May 30, 2025, with MD Ajit Kumar Jain and Company Secretary Harish Kamath. Management said consolidated EBITDA margin for FY25 was 18.94% versus 16.72% in FY24, above the around 18% guidance for the year; Q4 consolidated EBITDA margin was 18.24% versus 14.98% in Q4 FY24. Management said domestic business grew around 12% for FY25 and around 11% in Q4, and that market share improved to about 2.07% from 1.8% in March 2024, per IQVIA. Management said the company expects FY26 consolidated EBITDA margin to improve by around 1 percentage point, from 18.94% to around 20%, and said the current year's US business should contribute around INR 100 crore. Management said Unichem's FY25 EBITDA margin rose to about 12.55% and it guided for 8% to 10% growth for the next financial year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2025 | dividend Capex, Dividend / buy-back, Legal, Results | IPCA Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2025, recommended Final Dividend of Rs. 2 per equity share.AI summaryIpca Laboratories announced outcome of its Board meeting held on 29 May 2025, approving audited standalone and consolidated results for Q4 and FY ended 31 March 2025. Board recommended a final dividend of Rs. 2/- per share (200%) for FY 2024-25, subject to shareholder approval at the ensuing AGM, with 5 August 2025 (Tuesday) as the record date. Standalone FY2025 revenue from operations was Rs 6,677.92 crore and profit for the period from continuing operations was Rs 650.76 crore (FY2024: Rs 6,166.46 crore and Rs 530.41 crore). Board proposed altering the Object Clause of the Memorandum of Association to add green energy generation, including solar power, subject to a Special Resolution of members. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2025 | board outcome Capex, Dividend / buy-back, Results | IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.AI summaryIpca Laboratories' board met on 29 May 2025 and approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with auditors' reports and a declaration of unmodified audit opinions. Board recommended a final dividend of Rs 2/- per share (200%) for FY 2024-25, subject to shareholder approval at the ensuing AGM, with 5 August 2025 fixed as the record date. Standalone FY2025 revenue from operations was Rs 6,677.92 crore versus Rs 6,166.46 crore in FY2024; standalone profit for the year was Rs 650.76 crore versus Rs 530.41 crore. Board proposed altering the Object Clause of the Memorandum of Association to add green energy generation, including solar power for captive use, subject to a special resolution of members. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Mar 2025 | board outcome Acquisition, Capex, Legal | IPCA Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on March 28, 2025.AI summaryBoard of Ipca Laboratories approved, on 28 March 2025, the sale of its formulations manufacturing facility at T-139, MIDC, Tarapur, to M/s. V. S. International Pvt. Ltd. on a slump sale basis for Rs. 36.90 crores in cash; the sale is expected to complete on or before 30 June 2025, subject to approvals, and the unit's net written down value is Rs. 37.31 crores. The company said the products made at the unit can be manufactured at its other facilities, so the sale will have no impact on its business; the buyer is not a promoter group or related party. The board also approved acquiring 100% of Unichem Laboratories Ltd., Ireland from Unichem Laboratories Ltd., India for Rs. 4 crores all cash, subject to consents and approvals, to be renamed Ipca Laboratories (Europe) Ltd. The target was incorporated in 2011 to hold European dossier registrations and distribute Unichem India's products in Europe; its FY2024 turnover was Rs. 813.82 lakhs and profit after tax was Rs. 112.40 lakhs. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Feb 2025 | transcript Guidance, Results | IPCA Laboratories Limited has informed the Exchange about transcript ofconference call which was held on Thursday, 13th February, 2025 to discuss theCompany s Q3 FY25 earnings and business updateAI summaryIpca Laboratories filed the transcript of its Q3 FY25 post-results earnings conference call held on 13 February 2025, hosted by DAM Capital Advisors. Management (A.K. Jain, Managing Director) said standalone Q3 FY25 EBITDA margin was about 24.25% versus 18.52% in Q3 FY24; consolidated EBITDA margin was about 19.87% versus 16.1%. Management said standalone EBITDA margin for FY25 is likely to be about 23% to 24%, against earlier guidance of about 21%, and consolidated margin is expected at about 19.18% to 19.5%, against earlier guidance of about 18%. Management said the domestic formulation business grew about 6% in the quarter, API grew about 12%, and the company is ranked 16th in the IQVIA domestic pharma ranking for MAT December 2024. Management said the U.S. business via Unichem has shipped about 4 products, with 7 to 8 more in the pipeline, and has no meaningful impact on consolidated numbers yet. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2025 | results Results | Integrated Filing (Financial)AI summaryIpca Laboratories filed its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with limited review reports from its statutory auditors, approved by the Board on February 13, 2025. Standalone revenue from operations for Q3 FY25 (quarter ended Dec 31, 2024) was Rs 1,662.68 crores, against Rs 1,810.94 crores in the quarter ended Sept 30, 2024 and Rs 1,506.82 crores in the quarter ended Dec 31, 2023. Standalone net profit (profit for the period from continuing operations) for Q3 FY25 was Rs 267.56 crores, against Rs 136.94 crores in the corresponding quarter of the previous year; nine-month profit was Rs 715.81 crores. Standalone basic and diluted EPS for Q3 FY25 after exceptional items was Rs 10.55 per share (not annualised). The filing states that the results were reviewed by the Audit Committee and that the statutory auditors issued an unmodified report. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2025 | results Results | IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryIpca Laboratories filed its unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2024, approved by the Board on February 13, 2025, with a limited review report from the statutory auditors. Standalone revenue from operations for Q3 FY25 was Rs 1,662.68 crores, against Rs 1,810.94 crores in Q2 (Sept 30, 2024) and Rs 1,506.82 crores in Q3 FY24 (Dec 31, 2023). Standalone net profit for Q3 FY25 was Rs 267.56 crores, against Rs 136.94 crores in the year-ago quarter; nine-month profit was Rs 715.81 crores, against Rs 465.65 crores. Standalone profit before tax for the nine months ended Dec 31, 2024 was Rs 982.62 crores, against Rs 694.86 crores a year earlier, which included exceptional items. The filing also includes a press release and an integrated financial filing, and states that the meeting ran from 11.30 a.m. to 1.00 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2025 | board outcome Results | IPCA Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2025.AI summaryIpca Laboratories filed its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with limited review reports from its statutory auditors, approved by the Board on February 13, 2025. Standalone revenue from operations for the quarter ended Dec 31, 2024 was Rs 1,662.68 crore, and standalone profit for the period was Rs 267.56 crore, against Rs 136.94 crore in the year-ago quarter. Standalone revenue from operations for the nine months ended Dec 31, 2024 was Rs 5,039.48 crore, and profit for the period was Rs 715.81 crore. The Board meeting ran from 11.30 a.m. to 1.00 p.m. A press release on the Q3 and nine-month FY25 results was also enclosed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Nov 2024 | transcript Guidance, Results | IPCA Laboratories Limited has informed the Exchange about TranscriptAI summaryIpca Laboratories filed the transcript of its Q2 and H1 FY25 earnings conference call held on November 14, 2024. Management said domestic formulations grew 11% in Q2 FY25, with the company outpacing the IPM market (about 8% per IQVIA) and the acute and chronic segments; market share rose to 2.14% from 2.04% a year earlier. Management said standalone EBITDA margin was 22.89% in Q2 FY25 against 20.86% a year earlier, and consolidated EBITDA margin was 19.10% against 17.64%. Management revised its FY25 growth expectation to about 9% to 10%, from an earlier 10% to 11%, and said standalone EBITDA margin is likely to be around 22% against an earlier guideline of 21%. Management said Unichem synergies are still in progress, with the US business to be run through Unichem and first sales expected to reflect from Q3. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.